TEM
NASDAQTempus AI Inc.
Price$58.98-0.17 (-0.28%)
01:30 PM07:45 PM
News · 26 weeks134+4%
2026-03-152026-09-06
Mix6090d
- Insider27(45%)
- SEC Filings15(25%)
- Other11(18%)
- Analyst4(7%)
- Earnings3(5%)
Latest news
25 items- PRTempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare InnovationThe Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million Genomes Tempus AI, Inc. (NASDAQ:TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically optimized for AI-driven research. Once this dataset is complete, Tempus plans to expand the effort with the goal of reaching one million genomes. Existing pop
- PRTempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in CardiologyThe Initiative Will Pioneer an AI Agent That Functions as an Extension of the Clinician Team, Capable of Delivering and Coordinating Cardiovascular Care Without Direct Human Intervention Tempus AI, Inc. (NASDAQ:TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure. Funding provided through ARPA-H’s ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrmation) program will support the developme
- ANALYSTUBS initiated coverage on Tempus AI with a new price targetUBS initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $70.00
- ANALYSTRothschild & Co Redburn initiated coverage on Tempus AI with a new price targetRothschild & Co Redburn initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $67.00
- PRTempus to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceTempus AI, Inc. (NASDAQ:TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.A live audio webcast of the conversation will be available here.About TempusTempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in
- INSIDERDirector Doudna Jennifer A sold $44,312 worth of shares (676 units at $65.55) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 25,266 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan sold $1,934,244 worth of shares (30,846 units at $62.71) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERDirector Epstein David R sold $16,388 worth of shares (250 units at $65.55) as part of a pre-agreed trading plan, decreasing direct ownership by 0.80% to 30,844 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Tempus AI with a new price targetCantor Fitzgerald initiated coverage of Tempus AI with a rating of Overweight and set a new price target of $80.00
- INSIDERDirector West Nadja sold $207,000 worth of shares (3,000 units at $69.00) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 31,981 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- ANALYSTTempus AI upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Tempus AI from Neutral to Overweight and set a new price target of $76.00
- SECSEC Form S-4 filed by Tempus AI Inc.S-4 - Tempus AI, Inc. (0001717115) (Filer)
- INSIDERCEO and Chairman Lefkofsky Eric P sold $827,857 worth of shares (11,848 units at $69.87) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO and Chairman Lefkofsky Eric P sold $16,286,612 worth of shares (238,152 units at $68.39) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- SECSEC Form 144 filed by Tempus AI Inc.144 - Tempus AI, Inc. (0001717115) (Subject)
- INSIDERCEO, Diagnostics Schoenherr Thomas Edward increased direct ownership by 3% to 87,021 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan sold $1,000,020 worth of shares (14,286 units at $70.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- PRTempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGsECG-PH clearance adds pulmonary hypertension to Tempus’ FDA-cleared AI products for atrial fibrillation and low ejection fraction Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus’ growing cardiovascular portfolio, expanding the company’s suite of next-generation AI products aimed at identifying patients at risk for complex cardiac conditions. PH is characterized by stiffening a
- INSIDERCEO, Diagnostics Schoenherr Thomas Edward sold $929,990 worth of shares (17,314 units at $53.71) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 89,715 units (SEC Form 4) (for withholding tax)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO and Chairman Lefkofsky Eric P sold $6,577,840 worth of shares (132,591 units at $49.61), decreasing direct ownership by 6% to 2,098,130 units (SEC Form 4) (for tax liability)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERCEO, Data Fukushima Ryan sold $2,038,723 worth of shares (41,095 units at $49.61), decreasing direct ownership by 7% to 562,463 units (SEC Form 4) (withholding obligation)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERChief Financial Officer Rogers James William sold $2,696,444 worth of shares (48,842 units at $55.21) as part of a pre-agreed trading plan, decreasing direct ownership by 32% to 106,024 units (SEC Form 4) (tax liability)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDEREVP, Chief Legal Officer Polovin Andrew sold $1,542,674 worth of shares (30,075 units at $51.29) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 138,140 units (SEC Form 4) to satisfy tax liability4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERChief Accounting Officer Bartolucci Ryan M sold $306,342 worth of shares (6,175 units at $49.61), decreasing direct ownership by 8% to 67,866 units (SEC Form 4) (tax liability)4 - Tempus AI, Inc. (0001717115) (Issuer)
- SECSEC Form 144 filed by Tempus AI Inc.144 - Tempus AI, Inc. (0001717115) (Subject)
TEM FAQ
6 questionsWhere does TEM stock trade?
Tempus AI Inc. (TEM) is listed on NASDAQ.What sector and industry is TEM in?
Tempus AI Inc. operates in the Technology sector, Computer Software: Programming Data Processing industry.When did Tempus AI Inc. go public?
Tempus AI Inc. (TEM) completed its IPO in 2024.What are analysts saying about TEM?
Tempus AI Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral on 2026-09-09. Recent price targets cluster around $3500.00.What companies are similar to TEM?
Notable peers in the same industry include GOOGL (Alphabet Inc.), GOOG (Alphabet Inc.), META (Meta Platforms Inc.), APP (Applovin Corporation), NBIS (Nebius Group N.V.). Compare TEM side-by-side with any of them on Quantisnow.How can I track TEM on Quantisnow?
Quantisnow aggregates Tempus AI Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TEM to receive live email and push alerts on every new disclosure.